Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 10/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313004 | 0.82 | F13A1 (0.49) | — | |
| Hydrochloric Acid SCHEMBL6987068 | 0.77 | TNF (0.48) | CYP4F2CYP4A11TNF | |
| SCHEMBL1207466 | 0.77 | CYP4F2 (0.69) | CYP4F2CYP4A11CYP1A2 | |
| SCHEMBL15757946 | 0.77 | MTNR1A (0.56) | CYP4F2CYP4A11 | |
| SCHEMBL8962974 | 0.76 | TOP1 (0.47) | CYP4F2CYP4A11TNF | |
| SCHEMBL8962981 | 0.76 | CYP4F2 (0.44) | CYP4F2CYP4A11TNF | |
| SCHEMBL490753 | 0.76 | CYP4F2 (0.51) | CYP4F2CYP4A11TNFDPP4 | |
| SCHEMBL17722574 | 0.76 | CYP4F2 (0.54) | CYP4F2CYP4A11TNFDPP4 | |
| SCHEMBL27567553 | 0.75 | CYP4F2 (0.71) | CYP4F2CYP4A11CYP1A2 | |
| SCHEMBL2138518 | 0.75 | TNF (0.43) | CYP4F2CYP4A11TNFCYP1A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | CYP4F2 259/4885CYP4A11 417/4885TNF 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.